Prevalência da soropositividade do anti-HCV em pacientes dialisados

Abstract

This cross-sectional study evaluated the prevalence of anti-hepatitis antibodies and associated factors in dialysis patients. Data were collected from records of all patients receiving dialysis treatment [n=1,261] in the city of Porto Alegre, in Southern Brazil, from August to December 2003. The statistical analyses used were Chi-square and the linear tendency test. Prevalence ratios were also calculated. Multiple logistic regression analysis was performed through Cox regression. The prevalence of antihepatitis antibodies was of 29.1%, and was higher among patients treated by hemodialysis where there was no segregation of seropositive and seronegative patients and where dialyzers were reused. This association remained even when controlling for confounding factors. Patients who received blood transfusions had a linear increase in the prevalence of anti-hepatitis antibodies. The duration of dialysis treatment showed a dose-response curve with the prevalence of anti-hepatitis antibodies.

Prevalence of hepatitis C in patients with renal disease undergoing hemodialysis treatment

“…It is very similar to the study by Leão et al (2007), in which 10.7% were described in Juiz de Fora-MG (9,13) . However, when compared to data for the general population (1.38%), this seroprevalence of hepatitis C found in patients with renal failure undergoing hemodialysis is considered high (14,15) .…”

“…The prevalence of hepatitis C observed in the present study (10.17%) may be considered low when compared to the survey by Gomes et al (2006), which reported 29.1% of HCV infection in dialysis patients in Porto Alegre-RS. It is very similar to the study by Leão et al (2007), in which 10.7% were described in Juiz de Fora-MG (9,13) .…”

Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients

“…In addition, it must be highlighted that the dialyzer should only be reused 12 times, according to directive n.82/GM (2000) from the Ministry of Health [4]. All three of the units that were assessed followed the rules of the National Health Surveillance Agency (ANVISA) RCD n.154 related to the reuse of dialyzers and to the attending of patients with reactive hepatitis B and C and HIV [28,29].…”

“…Patients in dialysis units have been shown to have a higher risk for HCV infection compared with the prevalence of the antibody in groups of blood donors [3,4], which may contribute to the nosocomial dissemination in dialysis centers. There are several factors that are particularly related to the high prevalence rates, such as blood transfusions and the length of time that the patient has been undergoing hemodialysis [5,6].…”

Incidência de hepatite viral C em pacientes em hemodiálise no Brasil entre 2000 e 2003

“…Observou-se que 377 (49,4%) unidades de diálise não apresentaram paciente soroconvertido; no entanto, 50 (6,6%) delas apresentaram sete ou mais pacientes com soroconversão. Em estudo transversal realizado com 1.261 pacientes em hemodiálise de Porto Alegre, Rio Grande do Sul, verificou-se que a soroprevalência do anti-HCV foi maior entre pacientes atendidos nas unidades de diálise onde não havia separação dos pacientes positivos para anti-HCV e existia reutilização do dialisador 29 . Logo, são necessárias ações para prevenir a transmissão do HCV nas unidades de diálise.…”